

DAFTAR PUSTAKA

1. Kolb M, Dinh-Xuan AT, Brochard L. Guideline-directed management of COVID-19: Do's and Don'ts. *Eur Respir J.* 2021;57(4):1–10.
2. Birnhuber A, Fließner E, Gorkiewicz G, Zacharias M, Seeliger B, David S, et al. Between inflammation and thrombosis: Endothelial cells in COVID-19. *Eur Respir J.* 2021;58(3):1–12.
3. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol.* 2020;30(6):1–9.
4. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. *Arch Pharm Res.* 2021;44(1):99–116.
5. Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest.* 2020;130(9):4694–703.
6. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020;9(1):1123–30.
7. Liu X, Wang H, Shi S, Xiao J. Association between IL-6 and severe disease and mortality in COVID-19 disease: A systematic review and meta-analysis. *Postgrad Med J.* 2021;1–9.
8. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: Relevance for immunopathology of SARS-CoV-2. *Cytokine Growth Factor Rev.* 2020;53(1):13–24.
9. Sabaka P, Koščálová A, Straka I, Hodosy J, Lipták R, Kmotorková B, et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. *BMC Infect Dis.* 2021;21(1):4–11.
10. Renee L, Matos KKC. DOD Management of COVID. *Def Heal agency J.* 2020;1(1):5–19.
11. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19) -induced cytokine release syndrome (CRS)? *J Autoimmun Elsevier.* 2020;111(1):1–9.
12. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the

- controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur Respir J.* 2020;56(4):1–14.
13. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46(5):846–84.
 14. Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine Growth Factor Rev.* 2020;2(2):10–29.
 15. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020;9(1):1123–30.
 16. Belmehdi O, Hakkour M, Omari N El, Balahbib A, Guaouguaou FE, Benali T, et al. Molecular structure, pathophysiology, and diagnosis of COVID-19. *Biointerface Res Appl Chem.* 2021;11(3):10215–37.
 17. Nicola M, O’Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic - Review article. *Int J Surg.* 2020;77(March):206–16.
 18. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indones.* 2020;7(1):45–56.
 19. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J Am Med Assoc.* 2020;324(8):782–93.
 20. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J.* 2021;97(1147):312–20.
 21. Ratheesh M, Sunil S, Sheethal S, Jose SP, Sandya S, Ghosh OSN, et al. Anti-inflammatory and anti-COVID-19 effect of a novel polyherbal formulation (Imusil) via modulating oxidative stress, inflammatory mediators and cytokine storm. *Inflammopharmacology.* 2022;30(1):173–84.
 22. Signorini C, Pignatti P, Coccini T. How do inflammatory mediators, immune response and air pollution contribute to covid-19 disease severity? A lesson to learn. *Life.* 2021;11(3):1–27.
 23. Jarlhelt I, Nielsen SK, Jahn CXH, Hansen CB, Pérez-Alós L, Rosbjerg A, et al. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.

- Front Immunol. 2021;12(November):1–11.
24. Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier JF, Bayry J. Potential of regulatory T-cell-based therapies in the management of severe COVID-19. *Eur Respir J*. 2020;56(3):3–6.
 25. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol*. 2020;146(1):128–36.
 26. Jafarpour R, Pashangzadeh S, Dowran R. Host factors: Implications in immunopathogenesis of COVID-19. *Pathol Res Pract*. 2021;228(May):1536–47.
 27. Hussain M, Syed SK, Fatima M, Shaikat S, Saadullah M, Alqahtani AM, et al. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. *J Inflamm Res*. 2021;14(8):7225–42.
 28. Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. *PLoS One*. 2021;16(6 June):1–21.
 29. Ramatillah DL, Gan SH, Pratiwy I, Sulaiman SAS, Jaber AAS, Jusnita N, et al. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. *PLoS One*. 2022;17(11):1–14.
 30. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol*. 2020;11(June):1–4.
 31. Wang Y, Sibaii F, Lee K, J. Gill M, L. Hatch J. Level of IL-6 predicts Respiratory Failure in Hospitalized Symptomatic COVID-19 Patients. *medRxiv J*. 2021;1(165):1–13.
 32. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front Immunol*. 2020;11(July):1–13.
 33. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. *Inflamm Regen*. 2020;40(1):1–7.
 34. Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A, et al. The role of IL-6 and IL-6 blockade in COVID-19. *Expert Rev Clin Immunol*. 2021;17(6):601–18.
 35. Mahardhika GS, Tedjamartono TD, Buwono PW. High D-dimer and CRP Levels in an Asymptomatic COVID-19 Patient: A Case Report and Brief Literature Review. *Semin Nas Ris Kedokt*. 2021;2(1):167–77.

36. Schutgens RE. D-dimer in COVID-19: A Guide With Pitfalls. *HemaSphere*. 2020;4(4):1–22.
37. Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLoS One*. 2021;16(8 August 2021):1–13.
38. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. *J Intensive Care*. 2020;8(1):1–11.
39. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3. 3rd ed. *Pedoman Tatalaksana COVID-19*. Jakarta; 2020. 16–37 p.
40. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, Immunity, And disease. *Cold Spring Harb Perspect Biol*. 2014;6(10):1–16.
41. Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front Immunol*. 2021;12(2):1–10.
42. Aykal G, Esen H, Seyman D, Çaliskan T. Could IL-6 predict the clinical severity of COVID-19? *Turkish J Biochem*. 2021;46(5):499–507.
43. Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup. *N Engl J Med*. 2021;384(16):1564–75.
44. National Institutes of Health. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). *Nih*. 2021;2019(1):12–43.
45. Yang D. The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers. *Rheum Acta Open Access*. 2017;1(1):006–16.
46. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents*. 2020;55(5):1059–65.
47. Azmi NU, Puteri MU, Lukmanto D. Cytokine Storm in COVID-19: An Overview, Mechanism, Treatment Strategies, and Stem Cell Therapy Perspective. *Pharm Sci Res*. 2020;7(4):1–11.
48. Zhu X, Wang Y, Xiao Y, Gao Q, Gao L, Zhang W, et al. Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases. *Sci Rep*. 2022;12(1):1–14.
49. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an

- indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. *J Transl Med.* 2020;18(1):1–8.
50. Medison I, Morfi CW, Elesmita E, Asrini DN, Citra HU, Junaidi A, et al. Relationship between Initial CT Value , Inflammatory Markers , and Onset of Clinical Symptoms with Outcomes of Treatment Outcomes of COVID-19 Patients at Dr . M . Djamil General Hospit. *Biosci Med J Biomed Transl Res.* 2022;6(6):1914–28.
51. Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? *Pharmaceut Med.* 2020;34(4):223–31.
52. Khairisyaf O, Masrul Basyar, R.A Ananda Nuriman, Khairudin Hamdani, Hadya Gorga. Long Covid Incidence and Influencing Factors of Covid-19 Survivors in the Working Area of Lubuk Begalung Health Center, Padang. *Biosci Med J Biomed Transl Res.* 2022;6(4):1666–74.
53. Horberg MA, Watson E, Bhatia M, Jefferson C, Certa JM, Kim S, et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. *Nat Commun.* 2022;13(1):1–13.
54. van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract.* 2022;39(1):159–67.
55. Esin D, Sanli T, Altundag A, Giray S, Yildirim D. Relationship between disease severity and serum IL-6 levels in COVID-19 anosmia. *elsevier.* 2020;1(1):1–8.
56. Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. *PLoS One.* 2022;17(5 May):1–9.
57. Liu T, Zhang J, Yang Y, Ma H, Li Z, Yi J. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. *BMJ Open.* 2020;20:1–24.
58. Khan MS, Dogra R, Miriyala LKV, Salman FNU, Ishtiaq R, Patti DK, et al. Clinical characteristics and outcomes of patients with Corona Virus Disease 2019 (COVID-19) at Mercy Health Hospitals, Toledo, Ohio. *Plos one jr.* 2021;16(4):1–11.
59. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* 2020;395(10239):1763–70.
60. Witkowski JM, Fulop T, Bryl E. Immunosenescence and COVID-19. *elsevier.*

- 2020;1(January):1–10.
61. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study. *BMC Pulm Med*. 2021;21(1):1–11.
 62. Pál K, Molnar AA, Huțanu A, Szederjesi J, Branea I, Timár Á, et al. Inflammatory Biomarkers Associated with In-Hospital Mortality in Critical COVID-19 Patients. *Int J Mol Sci*. 2022;23(18):1–12.
 63. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res* [Internet]. 2020;6(4):00542–2020. Available from: <http://dx.doi.org/10.1183/23120541.00542-2020>
 64. Shimazui T, Nakada TA, Tateishi Y, Oshima T, Aizimu T, Oda S. Association between serum levels of interleukin-6 on ICU admission and subsequent outcomes in critically ill patients with acute kidney injury. *BMC Nephrol*. 2019;20(1):1–8.
 65. Tobias Herold, Vindi Jurinovic, Chiara Arnreich, Johannes C. Hellmuth, Michael von Bergwelt-Baildon MK and TW. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients Tobias. *medRxiv*. 2020;(165):1–13.
 66. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PLoS One*. 2020;15(12):1–11.
 67. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents*. 2020;55(5):1–10.
 68. Sari SDP, Mawanti WT, Martalena D, Listiyaningsih E, Avissa R, Latifah R, et al. Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels. *J thee Med Sci (Berkala Ilmu Kedokteran)*. 2021;53(3):218–25.
 69. Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohammed HM, Abdelazez AA, et al. Characteristics, outcomes and indicators of severity for covid-19 among sample of esna quarantine hospital's patients, egypt: A retrospective study. *Infect Drug Resist*. 2020;13:2375–83.
 70. Han Q, Guo M, Zheng Y, Zhang Y, De Y, Xu C, et al. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. *Front Pharmacol*. 2020;11(December):1–15.

71. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. *Biomed Pharmacother.* 2020;131:11–8.
72. Indriyani N, Sabri YS, Afriani A. Association Between Comorbidities and Outcome of COVID-19 Patients at dr. M. Djamil General Hospital Padang. *Respir Sci.* 2022;3(1):38–50.
73. Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, et al. Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm? *Front Cell Dev Biol.* 2020;8(July):1–8.

